Literature DB >> 11835525

Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy.

Joseph C K Leung1, Sydney C W Tang, Daniel T M Chan, Sing Leung Lui, Kar Neng Lai.   

Abstract

The mechanism of mesangial IgA deposition is poorly understood in IgA nephropathy (IgAN). Abnormal glycosylation of carbohydrate moieties in the hinge region of the IgA molecule has recently attracted much attention. In this report, we studied galactosylation and sialylation profiles in kappa- and lambda-IgA1 from patients with IgAN. Total serum IgA1 was isolated from patients with IgAN or healthy controls by jacalin-affinity chromatography. Six fractions of molecular weight (MW) 50-1,000 kDa were separated by fast protein liquid chromatography (FPLC). Four lectin-binding assays were used to study the sialylation and the presence of terminal galactose or N-acetylgalactosamine (GalNAc) in the O-linked carbohydrate moieties of kappa- or lambda-IgA1. Maackia amurensis agglutinin (MAA) and Sambucus nigra agglutinin (SNA) lectin recognize alpha(2,3)- and alpha(2,6)-linked sialic acid, respectively. Peanut agglutinin (PNA) and Helix aspersa (HA) lectin recognize terminal galactose and GalNAc, respectively. Reduced HA was demonstrated in macromolecular kappa or lambda-IgA1 (300-825 kDa) isolated from patients with IgAN (P < 0.05 compared with healthy controls). Lambda- but not kappa-IgA1 from patients with IgAN bound less to PNA (P < 0.05). The alpha(2,3)-linked sialic acid content in lambda- but not kappa-IgA1 of MW 150-610 kDa from patients was higher than that of controls (P < 0.005). The alpha(2,6)-linked sialic acid content in lambda-IgA1 (300-825 kDa) and kappa-IgA1 (150-610 kDa) from patients was also higher than that of controls. This unusual glycosylation and sialylation pattern of the lambda-IgA1 may have important implications for the pathogenesis of IgAN, as both the masking effect of sialic acid on galactose and the reduced galactosylation will hinder the clearance of macromolecular lambda-IgA1 by asialoglycoprotein receptor of hepatocytes. The negative charge from sialic acid may also favor mesangial deposition of macromolecular lambda-IgA1 in IgAN. Copyright 2002 Wiley‐Liss, Inc.angial IgA deposition is poorly understood in IgA ne

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11835525      PMCID: PMC6807889          DOI: 10.1002/jcla.2035

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  34 in total

1.  Aberrant glycosylation of IgA from patients with IgA nephropathy.

Authors:  D Baharaki; M Dueymes; R Perrichot; C Basset; R Le Corre; J Clèdes; P Youinou
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

2.  Studies of lymphocyte subpopulations and immunoglobulin production in IgA nephropathy.

Authors:  K N Lai; F M Lai; S H Chui; Y M Chan; G S Tsao; K N Leung; C W Lam
Journal:  Clin Nephrol       Date:  1987-12       Impact factor: 0.975

3.  Increased N-linked glycosylation leading to oversialylation of monomeric immunoglobulin A1 from patients with Sjögren's syndrome.

Authors:  C Basset; V Durand; C Jamin; J Clément; Y Pennec; P Youinou; M Dueymes; I M Roitt
Journal:  Scand J Immunol       Date:  2000-03       Impact factor: 3.487

Review 4.  Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.

Authors:  J Mestecky; J R McGhee
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

5.  O-linked oligosaccharide on IgA1 hinge region in IgA nephropathy. Fundamental study for precise structure and possible role.

Authors:  Y Hiki; A Horii; H Iwase; A Tanaka; Y Toda; K Hotta; Y Kobayashi
Journal:  Contrib Nephrol       Date:  1995       Impact factor: 1.580

6.  Charge and size of mesangial IgA in IgA nephropathy.

Authors:  R C Monteiro; L Halbwachs-Mecarelli; M C Roque-Barreira; L H Noel; J Berger; P Lesavre
Journal:  Kidney Int       Date:  1985-10       Impact factor: 10.612

7.  Increase of IgA-bearing peripheral blood lymphocytes in families of patients with IgA nephropathy.

Authors:  H Sakai; Y Nomoto; S Arimori; K Komori; H Inouye; K Tsuji
Journal:  Am J Clin Pathol       Date:  1979-09       Impact factor: 2.493

8.  Increased immunoglobulin-secreting cells in the blood of patients with active idiopathic IgA nephropathy.

Authors:  F P Schena; G Mastrolitti; A R Fracasso; A Pastore; N Ladisa
Journal:  Clin Nephrol       Date:  1986-10       Impact factor: 0.975

9.  Role of antigen size and charge in immune complex glomerulonephritis.

Authors:  K L Isaacs; F Miller
Journal:  Lab Invest       Date:  1982-08       Impact factor: 5.662

10.  Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.

Authors:  A C Allen; S J Harper; J Feehally
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

View more
  13 in total

1.  IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential.

Authors:  Michelle M Gomes; Andrew B Herr
Journal:  Springer Semin Immunopathol       Date:  2006-10-17

Review 2.  Glycosylation of IgA1 and pathogenesis of IgA nephropathy.

Authors:  Jan Novak; Bruce A Julian; Jiri Mestecky; Matthew B Renfrow
Journal:  Semin Immunopathol       Date:  2012-03-21       Impact factor: 9.623

3.  Clinicopathological significance of monoclonal IgA deposition in patients with IgA nephropathy.

Authors:  Hiroshi Nagae; Akihiro Tsuchimoto; Kazuhiko Tsuruya; Shota Kawahara; Yukiko Shimomura; Hideko Noguchi; Kosuke Masutani; Ritsuko Katafuchi; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2016-05-12       Impact factor: 2.801

Review 4.  Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers.

Authors:  Tongzhong Ju; Yingchun Wang; Rajindra P Aryal; Sylvain D Lehoux; Xiaokun Ding; Matthew R Kudelka; Christopher Cutler; Junwei Zeng; Jianmei Wang; Xiaodong Sun; Jamie Heimburg-Molinaro; David F Smith; Richard D Cummings
Journal:  Proteomics Clin Appl       Date:  2013-09-09       Impact factor: 3.494

5.  The clinicopathological characteristics and outcomes of IgA nephropathy with predominant lambda or kappa light-chain deposition.

Authors:  Shiren Sun; Wang Di; Rong Li; Xiaoxia Yang; Qin Jia; Chunmei Liu; Feng Ma
Journal:  Int Urol Nephrol       Date:  2021-11-18       Impact factor: 2.370

6.  Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding.

Authors:  Michelle M Gomes; Stephanie B Wall; Kazuo Takahashi; Jan Novak; Matthew B Renfrow; Andrew B Herr
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

Review 7.  Immunopathogenesis of IgAN.

Authors:  Jonathan Barratt; Alice C Smith; Karen Molyneux; John Feehally
Journal:  Semin Immunopathol       Date:  2007-09-13       Impact factor: 9.623

8.  IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1.

Authors:  Hitoshi Suzuki; Zina Moldoveanu; Stacy Hall; Rhubell Brown; Huong L Vu; Lea Novak; Bruce A Julian; Milan Tomana; Robert J Wyatt; Jeffrey C Edberg; Graciela S Alarcón; Robert P Kimberly; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

9.  Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes.

Authors:  Hitoshi Suzuki; Milan Raska; Koshi Yamada; Zina Moldoveanu; Bruce A Julian; Robert J Wyatt; Yasuhiko Tomino; Ali G Gharavi; Jan Novak
Journal:  J Biol Chem       Date:  2014-01-07       Impact factor: 5.157

Review 10.  Pathogenesis of Henoch-Schönlein purpura nephritis.

Authors:  Keith K Lau; Hitoshi Suzuki; Jan Novak; Robert J Wyatt
Journal:  Pediatr Nephrol       Date:  2009-06-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.